CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...
Phase 1
Pembroke Pines, Florida, United States and 12 other locations
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Hollywood, Florida, United States and 31 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
Hollywood, Florida, United States and 211 other locations
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple...
Phase 1, Phase 2
Miami, Florida, United States and 14 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Miami, Florida, United States and 46 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Pembroke Pines, Florida, United States and 48 other locations
determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...
Phase 2
Miami, Florida, United States and 39 other locations
of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...
Phase 1
Plantation, Florida, United States and 21 other locations
of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...
Phase 1
Miami, Florida, United States and 17 other locations
provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...
Phase 2
Miami, Florida, United States and 78 other locations
Clinical trials
Research sites
Resources
Legal